Neurocrine Biosciences announced today that it has discontinued tests on technology for the treatment of multiple sclerosis (MS).
The firm said that its Phase II clinical trial, which used altered peptide ligand (APL) technology, had not proved effective or met its primary endpoint.
"Our Phase II study in multiple sclerosis patients showed APL-MS to have an excellent safety profile, but unfortunately the study did not achieve statistical significance in efficacy in the 157 patients tested over the nine month treatment period," said Wendell Wierenga, the firm's executive vice president of research and development.
The company claims that the APL technology will undergo further tests to discover if it can be used in the treatment of type one diabetes, with results expected later this year.
There is currently no cure for multiple sclerosis, which is believed to affect around 85,000 people in the UK.